Drug updated on 11/27/2024
| Dosage Form | Tablet (oral; 80 mg and 240 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations
Latest News
Summary
- This summary is based on the review of one systematic review/meta-analysis. [1]
- Lazertinib plus amivantamab and osimertinib plus chemotherapy demonstrated high and comparable efficacy in improving progression-free survival in patients with advanced Epidermal Growth Factor Receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).
- Subgroup analyses suggested slight variations in treatment efficacy based on mutation types and patient demographics; specific details of these differences were not provided.
- Combination treatments, including lazertinib plus amivantamab and osimertinib plus chemotherapy, demonstrated higher rates of adverse events compared to monotherapies, encompassing first, second, and third-generation EGFR-Tyrosine Kinase Inhibitors (TKI).
- No details on the nature or severity of adverse events were provided, but combination therapies were noted for increased safety concerns relative to other treatments.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Lazcluze (lazertinib) Prescribing Information. | 2024 | Janssen Biotech, Inc., Horsham, PA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis | 2024 | Bmc Cancer |